Login / Signup
Xifeng Dong
ORCID
Publication Activity (10 Years)
Years Active: 2021-2021
Publications (10 Years): 3
Top Topics
Pet Ct
Tyrosine Kinase
Advanced Non Small Cell Lung Cancer
Phase Iii
Top Venues
Thoracic cancer
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Fengtan Li
,
Xifeng Dong
Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
Thoracic cancer
12 (23) (2021)
Weisan Zhang
,
Xifeng Dong
Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
(2021)
Yating Yu
,
Xifeng Dong
,
Meifeng Tu
,
Huaquan Wang
Primary mediastinal large B cell lymphoma.
Thoracic cancer
12 (21) (2021)